Ceapro Inc.
TSXV:CZO Rapporto sulle azioni
Cap. di mercato: CA$17.6m
This company is no longer active The company may no longer be operating, as it may be out of business. Find out why through their latest events.
See Latest Events Ceapro Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Ceapro ha un patrimonio netto totale di CA$27.9M e un debito totale di CA$0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente CA$31.4M e CA$3.6M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti CA$8.84m Patrimonio netto CA$27.86m Totale passività CA$3.59m Totale attività CA$31.45m
Aggiornamenti recenti sulla salute finanziaria
Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity Jun 08
Mostra tutti gli aggiornamenti
Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity Jun 08 Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction. Jun 05
Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.
Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022) Nov 30
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases Nov 29
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases Nov 28
Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022) Aug 31
The Returns At Ceapro (CVE:CZO) Aren't Growing Aug 09
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director Jun 08
First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022) May 27
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases May 24
Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021) Apr 14
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets Dec 23
Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021) Nov 10
Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets Nov 08
Returns At Ceapro (CVE:CZO) Are On The Way Up Oct 15
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers Oct 14
Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021) Aug 24
Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer Jul 13
Ceapro's (CVE:CZO) Returns Have Hit A Wall Jun 17
Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee Jun 08
High number of new directors May 31
First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021) May 19
Insufficient new directors Apr 27
Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors Apr 20
Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020) Apr 14
Ceapro Inc., Annual General Meeting, Jun 01, 2022 Apr 02
Ceapro Appoints Ronnie Miller to its Board of Directors Mar 04
Ceapro Appoints Ronnie Miller to its Board of Directors Mar 03
Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends Nov 19
Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020) Nov 19
Second quarter 2021 earnings released Aug 27
Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital Jul 20
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent May 27
Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors May 27
First quarter 2021 earnings released May 22
Estimating The Fair Value Of Ceapro Inc. (CVE:CZO) Apr 29
Full year 2020 earnings released Apr 24
New 90-day low: CA$0.63 Mar 10
Will Ceapro (CVE:CZO) Multiply In Value Going Forward? Mar 01
Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)? Feb 01
New 90-day high: CA$0.79 Jan 27
Estimating The Fair Value Of Ceapro Inc. (CVE:CZO) Jan 06
Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? Nov 28
New 90-day high - CA$0.84 Aug 19
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( CA$14.8M ) di CZO superano le sue passività a breve termine ( CA$1.7M ).
Passività a lungo termine: Le attività a breve termine di CZO ( CA$14.8M ) superano le sue passività a lungo termine ( CA$1.9M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CZO è esente da debiti.
Riduzione del debito: CZO non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 2.7%.
Copertura del debito: CZO non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo .
Copertura degli interessi: CZO non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
